Limax Biosciences, Inc.

Despite advances in surgical glues and hemostatic patches, 30-50% of surgeries still suffer from bleeding related complications. Limax Biosciences has developed a next generation, stretchable hydrogel-based tissue adhesive to revolutionize treatments for injuries inside and outside the body. Existing hemostatic dressings and sealants have weak tissue adhesion that result in leaks, tissue rigidity, and cytotoxicity. Limax’s degradable, hydrogel-based material addresses these limitations through strong and rapid adhesion to wet tissue surfaces at 10-100x higher the strength of competitors. This patent-protected platform technology can be used in several indications throughout the body including soft tissue reinforcement and local drug delivery.